What Does Pfizer’s Read Have To Say About It? A Lot, Actually
Executive Summary
Pfizer CEO Ian Read voiced his opinions on some of industry’s hottest topics – everything from the pricing of Sovaldi to M&A to the latest innovations, like gene therapy – during a far-ranging discussion at the BIO CEO & Investor conference Feb. 10.
You may also be interested in...
Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.